MRgFUS治疗子宫腺肌症相关痛经的安全性及短期疗效
该回顾性单中心队列纳入62例经MRI确诊子宫腺肌症伴痛经的患者,均接受MRgFUS治疗。术后即刻平均非灌注体积比为69.12%±17.64%,VAS评分从基线6.68±2.13降至术后3个月3.69±1.95、6个月2.72±1.40。研究认为MRgFUS技术可行且安全性好,但12个月随访仅21.0%患者,长期疗效需前瞻性对照研究进一步验证。
要点
- MRgFUS术后即刻平均NPVR达69.12%±17.64%,可作为消融即刻评估指标。
- 痛经VAS评分术后6个月降至2.72±1.40,短期症状改善明显。
- 12个月随访丢失率高,报告长期疗效时需谨慎表述。
核心结论
- MRgFUS在该回顾性队列中技术可行且安全性良好,短期可改善痛经并早期缩减腺肌症病灶体积。
- 12个月随访仅21.0%的患者且缺乏对照组,长期疗效应谨慎解读并需前瞻性对照研究证实。
研究设计与样本
- 回顾性单中心队列研究,纳入2018年10月至2021年3月间接受MRgFUS治疗的62例经MRI确诊的子宫腺肌症伴痛经患者。
- 在MRI上测量子宫体积、腺肌症病灶体积及非灌注体积,非灌注体积比定义为非灌注体积除以病灶体积。
- 痛经严重程度采用视觉模拟评分评估,随访数据按3个月、6个月及12个月可用病例进行分析。
关键影像表现/征象
- MRI上可测得术后即刻平均非灌注体积比为69.12%±17.64%,提示消融后无灌注区占病灶比例较高。
- 腺肌症病灶平均体积由基线83.72±84.02 cm³降至3个月62.66±66.31 cm³、6个月56.09±66.67 cm³,12个月亚组为68.53±87.04 cm³。
- 子宫平均体积由基线201.38±126.17 cm³降至3个月174.97±108.32 cm³和6个月164.86±108.58 cm³,但12个月小亚组为205.45±125.76 cm³。
诊断标准与关键数值
- 术后即刻平均非灌注体积比为69.12%±17.64%,用于评估MRgFUS消融效果。
- VAS评分从基线6.68±2.13降至3个月3.69±1.95、6个月2.72±1.40、12个月3.38±1.45。
- 12个月MRI随访仅13/62例即21.0%的患者可用,病灶体积及子宫体积数据基于该小样本亚组。
临床应用与阅片要点
- 术后MRI应常规测量非灌注体积并计算NPVR,用于客观记录消融范围。
- 3个月和6个月随访可观察腺肌症病灶体积和子宫体积缩小趋势,辅助评估治疗反应。
- 报告12个月结果时需注明随访丢失率高,避免将小亚组数据外推至全部患者。
局限性
- 12个月随访仅21.0%的患者,长期疗效数据严重不足。
- 本研究为回顾性单中心队列,无对照组,无法排除安慰剂效应或自然病程影响。
- 原文未报告严重手术相关并发症,但未说明轻微并发症或不良事件的系统评价方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the safety and short-term efficacy of magnetic resonance-guided high-intensity focused ultrasound surgery (MRgFUS) for adenomyosis-associated dysmenorrhea.
MATERIALS AND METHODS: This retrospective single-center cohort included 62 patients with MRI-confirmed adenomyosis and dysmenorrhea who underwent MRgFUS between October 2018 and March 2021. Uterine volume, adenomyosis lesion volume, and non-perfused volume (NPV) were measured on MRI. The non-perfused volume ratio (NPVR) was calculated as NPV divided by lesion volume. Dysmenorrhea severity was assessed using the visual analogue scale (VAS). Follow-up data were analyzed as available cases at 3, 6, and 12 months.
RESULTS: All 62 patients completed MRgFUS. The mean immediate NPVR was 69.12% ± 17.64%. MRI follow-up was available in 53/62 patients (85.5%) at 3 months, 38/62 (61.3%) at 6 months, and 13/62 (21.0%) at 12 months. Mean uterine volume decreased from 201.38 ± 126.17 cm3 at baseline to 174.97 ± 108.32 cm3 at 3 months and 164.86 ± 108.58 cm3 at 6 months, but was 205.45 ± 125.76 cm3 in the small 12-month subgroup. Mean adenomyosis lesion volume decreased from 83.72 ± 84.02 cm³ at baseline to 62.66 ± 66.31 cm3, 56.09 ± 66.67 cm3, and 68.53 ± 87.04 cm3 at 3, 6, and 12 months, respectively. Mean VAS score decreased from 6.68 ± 2.13 at baseline to 3.69 ± 1.95 at 3 months, 2.72 ± 1.40 at 6 months, and 3.38 ± 1.45 at 12 months. No serious procedure-related complications occurred.
CONCLUSION: MRgFUS was technically feasible and appeared safe in this retrospective cohort, with encouraging short-term improvement in dysmenorrhea and early reduction in adenomyosis lesion volume. Because 12-month follow-up was available for only 21.0% of patients and no control group was included, long-term efficacy should be interpreted cautiously and confirmed in prospective controlled studies.
引用
- Zhang, Li, Li, et al. Safety and efficacy of magnetic resonance-guided high-intensity focused ultrasound surgery (MRgFUS) in adenomyosis with dysmenorrhea. Abdom Radiol (NY). 2026. PMID: 42701971. doi:10.1007/s00261-026-05772-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。